Merck posted robust top-line gains driven by enduring demand for blockbuster oncology drug Keytruda and rapid market adoption of newly launched Winrevair.

Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.